UBQU (Ubiquitech Software) Cash Conversion Cycle: 173.38 (As of Aug. 2023)


What is Ubiquitech Software Cash Conversion Cycle?

Ubiquitech Software UBQU -95.00% Cash Conversion Cycle is 173.38 as of Aug. 2023.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Ubiquitech Software's Days Sales Outstanding for the three months ended in Aug. 2023 was 0.
Ubiquitech Software's Days Inventory for the three months ended in Aug. 2023 was 264.63.
Ubiquitech Software's Days Payable for the three months ended in Aug. 2023 was 91.25.
Therefore, Ubiquitech Software's Cash Conversion Cycle (CCC) for the three months ended in Aug. 2023 was 173.38.


Ubiquitech Software  (OTCPK:UBQU) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Ubiquitech Software Cash Conversion Cycle Related Terms


Ubiquitech Software Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Ubiquitech Software's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ubiquitech Software Cash Conversion Cycle Chart

Ubiquitech Software Annual Data
Trend Aug08
Cash Conversion Cycle
0.00

Ubiquitech Software Quarterly Data
Nov07 Feb08 May08 Aug08 Nov08 Feb09 May09 Aug09 Nov09 Feb10 May10 Aug22 Aug23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.63 173.38

UBQU vs ZTS: Cash Conversion Cycle Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ubiquitech Software's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ubiquitech Software Cash Conversion Cycle vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ubiquitech Software's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Ubiquitech Software's Cash Conversion Cycle falls into.



Ubiquitech Software Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Ubiquitech Software's Cash Conversion Cycle for the fiscal year that ended in Aug. 2008 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

Ubiquitech Software's Cash Conversion Cycle for the quarter that ended in Aug. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+264.63-91.25
=173.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 173.38 mean?
Ubiquitech Software (UBQU) has a Cash Conversion Cycle of 173.38 as of Aug. 2023. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Ubiquitech Software and its competitors.
Is Ubiquitech Software's Cash Conversion Cycle too high?
Ubiquitech Software's current Cash Conversion Cycle is 173.38. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Ubiquitech Software's value of 173.38 is 18.9% above this industry median.
How does Ubiquitech Software's Cash Conversion Cycle compare to ZTS?
Ubiquitech Software's Cash Conversion Cycle of 173.38 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Ubiquitech Software's value of 173.38 is 18.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ubiquitech Software's current Cash Conversion Cycle of 173.38 is 18.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Ubiquitech Software and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ubiquitech Software's current Cash Conversion Cycle is 173.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ubiquitech Software stock overvalued right now?
Ubiquitech Software (UBQU) has a current Cash Conversion Cycle of 173.38. The current Cash Conversion Cycle is 173.38 and 18.9% above the Drug Manufacturers industry median of 145.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Ubiquitech Software (UBQU), the current Cash Conversion Cycle is 173.38 as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ubiquitech Software Business Description

Address 3570 East 12th Avenue, Denver, CO, USA, 80206
Ubiquitech Software Corp is a United States-based multi-media, multi-faceted company. It is engaged in utilizing world-wide internet marketing, direct response television, radio, and traditional marketing to drive traffic to the new industries. The company also focuses on developing Cannabidiol (CBD) Hemp derived products. It owns the proprietary CBD brand CannazALL. The company offers the products through its internally designed and operated web portal.